News & Events
< Back to News Overview
Pharmaxis Completes Enrolment In Aridol Copd Trial
11 / 04 / 2006
Specialist pharmaceutical company Pharmaxis Ltd (ASX:PXS, NASDAQ:PXSL) announced today that it has completed enrolment in its clinical trial to test Aridol's ability to predict response to treatment in patients with Chronic Obstructive Pulmonary Disease (COPD).
The trial commenced in September 2005 and is being conducted at 11 hospitals in five states across Australia. Patients who volunteer for the trial receive an Aridol test followed by 12 weeks of treatment with an inhaled steroid to control lung inflammation. The trial will record differences in lung function, quality of life and the general health of the patient. Data from the study is expected to be available during the July - September quarter.
Alan Robertson, Pharmaxis chief executive officer said: Currently, there is no simple test
to identify the one in five patients with COPD that will have a positive clinical response to
inhaled anti-inflammatory drugs. We anticipate that Aridol can play an important role in
the clinical management of this disease. COPD is the world's fourth leading cause of death and for most people affected, there is no effective therapy. We expect Aridol to fill this gap.'
The trial commenced in September 2005 and is being conducted at 11 hospitals in five states across Australia. Patients who volunteer for the trial receive an Aridol test followed by 12 weeks of treatment with an inhaled steroid to control lung inflammation. The trial will record differences in lung function, quality of life and the general health of the patient. Data from the study is expected to be available during the July - September quarter.
Alan Robertson, Pharmaxis chief executive officer said: Currently, there is no simple test
to identify the one in five patients with COPD that will have a positive clinical response to
inhaled anti-inflammatory drugs. We anticipate that Aridol can play an important role in
the clinical management of this disease. COPD is the world's fourth leading cause of death and for most people affected, there is no effective therapy. We expect Aridol to fill this gap.'